Showing results (191-200 of 203) with videos related to
Sort By:
Pageof 21
Clinical & Experimental Metastasis|February 6, 2002
Analysis of mechanisms underlying BRMS1 suppression of metastasisR S Samant, M J Seraj, M M Saunders, et al.ACS Chemical Biology|July 2, 2025
Mediator Kinase Inhibitor Selectivity and Activity in Colorectal CancerMaria J Ortiz-Ruiz, Olajumoke Popoola, Konstantinos Mitsopoulos, et al.The Journal of Clinical Investigation|September 23, 2021
RAF1 amplification drives a subset of bladder tumors and confers sensitivity to MAPK-directed therapeuticsRaie T Bekele, Amruta S Samant, Amin H Nassar, et al.Gastroenterology|August 25, 2015
Nuclear Localization of DNAJB6 Is Associated With Survival of Patients With Esophageal Cancer and Reduces AKT Signaling and Proliferation of Cancer CellsValen Zhuoyou Yu, Victor Chun-Lam Wong, Wei Dai, et al.Cancer Discovery|October 10, 2015
Dual Roles of RNF2 in Melanoma ProgressionKunal Rai, Kadir C Akdemir, Lawrence N Kwong, et al.Blood|May 23, 2018
The presence of large focal lesions is a strong independent prognostic factor in multiple myelomaLeo Rasche, Edgardo J Angtuaco, Terri L Alpe, et al.Cell Reports|April 27, 2017
Systematic Epigenomic Analysis Reveals Chromatin States Associated with Melanoma ProgressionPetko Fiziev, Kadir C Akdemir, John P Miller, et al.Nature Chemical Biology|October 27, 2015
A selective chemical probe for exploring the role of CDK8 and CDK19 in human diseaseTrevor Dale, Paul A Clarke, Christina Esdar, et al.Oncoimmunology|January 3, 2024
A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignanciesChia-Chi Lin, Elena Garralda, Patrick Schöffski, et al.Journal for Immunotherapy of Cancer|February 26, 2022
Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignanciesPatrick Schöffski, Daniel S W Tan, Miguel Martín, et al.Pageof 21